Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2756 - Percutaneous biliary drainage in malign obstructive jaundice: Is it really necessary for all patients with malign obstructive jaundice?


09 Oct 2016


Poster display


cemil Hocazade


Annals of Oncology (2016) 27 (6): 455-461. 10.1093/annonc/mdw384


C. Hocazade1, I. Akmangit2, B. Sever Sayın2, M. Doğan3, Y. Bozkaya1, G.U. Erdem1, N. Zengin1

Author affiliations

  • 1 Medical Oncology, Ankara Numune Education and Research Hospital, 06100 - Ankara/TR
  • 2 Interventional Radiology, Ankara Numune Education and Research Hospital, Ankara/TR
  • 3 Medical Oncology, Ankara Numune Education and Research Hospital, 06200 - Ankara/TR


Abstract 2756


Malign obstructive jaundice (MOJ) in cancer is due to liver metastasis and/or biliary duct compression. Percutaneous biliary drainage (PBD) is a palliative procedure. Prognostic & predictive factors are needed for selection of the cancer patients who will get more benefit from PBD in MOJ. We evaluated cancer patients (CP) who had PBD for MOJ for clinicopathological features (CPF) & survival outcomes besides potential predictive markers for PBD.


110 CP who had PBD for MOJ between 2010 & 2016 were evaluated retrospectively. The correlation between biochemical values, CPF (extrahepatic metastasis (EM), obstruction cause (OC), stent localization) & total bilirubin (TB) was evaluated by ROC analysis. The CP were analyzed according to TB after PBD [groups A: normal (1 mg/dl or 20% decrease), C: stable/increase.


Median age was 60 (28-82) years. 57 were male. In univariate analysis, EM & OC were significant factors with concordance to biochemical values. Albumin (p = 0.007, OR: 5.2, 1,5-17,1), LDH (p = 0.041, OR:2.5, 1.02-6,2) & OC (p = 0.019, OR:3.4, 1.2-9,9) remained significant in multivariate analysis. The CP were grouped according to these risk factors (RF): groups 1 (22,7%: no RF), 2 (64,5%: 1-2 RF), 3 (12,7%: >3 RF). TB normalization & OS after PBD are shown in table 1. Stenting proximal to choledoc had better TB normalization (44,7% vs 17,6%, p = 0.006).Chemotherapy rates were as 60% for group A, 36,8% for group B & 21,9% for group C (p = 0.004). 6-months OS was 41,3% for patients receiving chemotherapy & 17,7% for others (p 


Group A* (%) Group A* (%) OS
Total bilirubin (mg/dl)
>13 19,6 18,5
2,5 12,1 6

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.